Brian Gregory Wowk

6391224, May 21, 2002

Sep 21, 1999

09/400791

Brian Wowk - Corona CA

21 - Rancho Cucamonga CA

C09K 318

252 70, 47 2, 106 13, 252 71, 252 73, 252 77

Polyvinyl alcohol and related compounds are provided that inhibit the freezing of water and water solutions. These synthetic compounds preferentially bind and inhibit ice nucleating surfaces in a manner similar to natural antifreeze proteins. The resulting inhibition allows water and water solutions to supercool without ice formation to temperatures below the thermodynamic freezing point. The freezing inhibition occurs at concentrations as small as one part per million, although concentrations up to one part per hundred are preferred. These polyvinyl alcohol additives are very useful for enhancing the performance of antifreeze formulations, biological cryopreservation solutions, and for preventing frost damage to plants and other industrial products and processes.

6395467, May 28, 2002

Sep 21, 1999

09/400793

Gregory M. Fahy - Corona CA, 92879
Brian Wowk - Corona CA, 92879

A01N 100

435 13, 435 11, 435260

A cryoprotectant solution used for preserving biological material comprising cells is disclosed. The solution comprises dimethyl sulfoxide, an amide such as formamide, urea, acetamide, hydroxyurea, N-methyl formamide, and ethylene glycol or ethylene glycol in combination with propylene glycol wherein the propylene glycol replaces less than 8% w/v of the ethylene glycol.

6616858, Sep 9, 2003

Nov 30, 2000

09/726857

Greg Fahy - Corona CA, 92879
Brian Wowk - Corona CA, 92879

C09K 318

252 70, 47 2, 106 13, 252 71, 252 73, 252 77, 435 11, 435 13, 435260

Linear polymers of glycerol can prevent or delay ice nucleation in a variety of contexts. Polyglycerol can also be employed in combination with other ice control agents, such as polyvinyl alcohol/polyvinyl acetate copolymers and antifreeze proteins, to provide antinucleation effects that are superior to those of either polyglycerol or the co-antinucleator alone. Polyglycerol has a number of advantageous physical and toxicological properties, such as extreme water solubility, non-toxicity to human beings, non-toxicity to animal tissues and organs in vitro even at extreme concentrations, minimal foaming tendency, minimal retention on hydrophobic surfaces, and stability in solution without the need for periodic heating to reactivate its antinucleation properties.

6988370, Jan 24, 2006

Jun 14, 2004

10/867987

Michael Iarocci - Patchogue NY, US
Stephen Valentine - New York NY, US
Brian Wowk - Corona CA, US

F17C 11/00

62 451, 62 501

A cryogenic storage system for cryogenic storage using liquid refrigerant is provided. The cryogenic storage system includes first and second vacuum vessels, a vacuum source, a quantity of a liquid refrigerant, and at least one temperature control assembly. An insulating wall may be provided on an interior surface of one of the vessels. A common vacuum condition is provided in voids that are present in the wall of the first and second vessels as well as in the insulating wall. The at least one temperature control assembly includes a power supply, a temperature sensor, a heater, and a conductive element. The at least one conductive element provides a link or thermal coupling between a space defined in the first vessel and the liquid refrigerant stored in the second vessel.

7278278, Oct 9, 2007

Jun 9, 2004

10/864921

Brian Wowk - Corona CA, US
Michael Iarocci - Patchogue NY, US

21st Century Medicine, Inc. - Rancho Cucamonga CA

F25D 3/08

62371, 62 451

The present invention provides devices and methods for the cryogenic storage of biological material. Devices of the invention are useful for storing material at a cryogenic temperature. The devices include a temperature chamber defined by a thermally-conductive container and at least one layer of thermal insulation surrounding the thermally-conductive container. Some embodiments utilize one or more heat sources thermally connected to the thermally conductive container. Other embodiments are arranged so that no net flow of heat occurs from the temperature chamber when the temperature chamber is at a set target temperature. Also provided are methods of using the devices.

7299641, Nov 27, 2007

Dec 12, 2005

11/299578

Michael Iarocci - Patchogue NY, US
Stephen Valentine - New York NY, US
Brian Wowk - Corona CA, US

The Stasis Foundation - Fort Lauderdale FL

F17C 3/08
F17C 7/02

62 451, 62 501

A cryogenic storage system for cryogenic storage using liquid refrigerant is provided. The cryogenic storage system includes first and second vacuum vessels, a vacuum source, a quantity of a liquid refrigerant, and at least one temperature control assembly. An insulating wall may be provided on an interior surface of one of the vessels. A common vacuum condition is provided in voids that are present in the wall of the first and second vessels as well as in the insulating wall. The at least one temperature control assembly includes a power supply, a temperature sensor, a heater, and a conductive element. The at least one conductive element provides a link or thermal coupling between a space defined in the first vessel and the liquid refrigerant stored in the second vessel.

20070190517, Aug 16, 2007

Sep 16, 2004

10/571968

Gregory Fahy - Corona CA, US
Brian Wowk - Corona CA, US

A01N 1/00

435001100

Methods and compositions are provided for the introduction and washout of vitrifiable concentrations of cryoprotectant in organs and tissues. The methods comprise cooling the organ to below −10 C. by perfusion with a solution having a freezing point below −10 C., a temperature from −10 to −40 C., and a tonicity from 1.1 to 2.0 times isotonic, after previous perfusion with said solution for a time insufficient for approximate osmotic equilibration of the organ with the solution. The methods further comprise increasing the concentration of cryoprotectant further at a temperature from −10 to −40 C. to prepare the organ or tissue for vitrification. The methods further comprise cooling and vitrifying the organ, rewarming it, and perfusing the organ with a vitrifiable concentration of cryoprotectant that is the same as or less than the concentration used for vitrification, without the addition of an osmotic buffering agent. Rewarming is accomplished either by rapid (>1C./min, and preferably −0.2-20 C./min) elevation of arterial perfusate temperature from below −20 C. to above −15 C. during continuous perfusion of the organ or by perfusing the organ with pre-warmed arterial perfusate at >−15 C. Extraordinarily effective multicomponent compositions are also provided for the process, particularly involving a vitrification solution whose warming rate after vitrification can be